Resistance Mutations to Broadly Neutralizing Antibodies Destabilize Hemagglutinin and Attenuate H1N1 Influenza Virus
Viruses · 2025
DOI: 10.3390/v18010032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Guohua Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Hemagglutinin Glycoproteins, Influenza Virus, Influenza A Virus, H1N1 Subtype, Antibodies, Viral. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases (NIAID) under Collaborative Influenza Vaccine Innovation Centers, National Institute of Allergy and Infectious Diseases under Centers of Excellence for Influenza Research and Response.
Abstract (Originalsprache)
Because antigenic drift primarily generates amino-acid changes in the membrane-distal hemagglutinin (HA) head, broadly neutralizing antibodies (bNAbs) are being developed to target conserved epitopes in the membrane-proximal stem. Mutations to HA2 residue A44, a buried residue beneath the central stem epitope, in 2009 H1N1 viruses have been shown to cause resistance to stem-binding bNAbs. Here, we introduced A44V and A44T mutations into A/Tennessee/1-560/2009 (TN09) and A/Puerto Rico/15/2018 (PR18) and investigated their effects in cell culture, mice, and ferrets. In both virus strains, the mutations decreased HA and virus stability and decreased bNAb binding and neutralization in vitro. The mutations reduced pathogenicity and lung replication in DBA/2J mice. Ferrets were inoculated with PR18 wild-type (WT) or A44V virus, and the A44V mutation reduced day-1 and peak nasal virus titers. Airborne transmission in the A44V group occurred only after genotypic reversion (HA2-V44A) or acquisition of a distal re-stabilizing mutation (HA2-I77M). Compared to WT, an engineered PR18 virus containing both HA2 mutations (A44V and I77M) had similar growth and pathogenicity in mice in addition to decreased binding and neutralization by bNAbs. Overall, this work provides insight into the role of HA stability during HA stem-epitope remodeling that results in virus resistance to stem-binding bNAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
- Department of Biomolecular Engineering, University of California-Santa Cruz, Santa Cruz, CA 95064, USA.
ORCID-Profile: Po-Ling Chen, Rebecca M DuBois, Richard J Webby, Charles J Russell
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases (NIAID) under Collaborative Influenza Vaccine Innovation Centers
- National Institute of Allergy and Infectious Diseases under Centers of Excellence for Influenza Research and Response
- St. Jude Children’s Research Hospital
- American Lebanese Syrian Associated Charities
Zitieren
APA
Yang, G., Chen, P. L., Rovito, S. W., Minari, K., Writt, H. N., DeBeauchamp, J., Crumpton, J. C., Kercher, L., DuBois, R. M., Webby, R. J., & Russell, C. J. (2025). Resistance Mutations to Broadly Neutralizing Antibodies Destabilize Hemagglutinin and Attenuate H1N1 Influenza Virus. Viruses. https://doi.org/10.3390/v18010032
Vancouver
Yang G, Chen PL, Rovito SW, Minari K, Writt HN, DeBeauchamp J, et al. Resistance Mutations to Broadly Neutralizing Antibodies Destabilize Hemagglutinin and Attenuate H1N1 Influenza Virus. Viruses. 2025. doi:10.3390/v18010032
BibTeX
@article{Yang2025,
author = {Yang, Guohua and Chen, Po-Ling and Rovito, Samuel W and Minari, Karine and Writt, Haley N and DeBeauchamp, Jennifer and Crumpton, Jeri Carol and Kercher, Lisa and DuBois, Rebecca M and Webby, Richard J and Russell, Charles J},
title = {Resistance Mutations to Broadly Neutralizing Antibodies Destabilize Hemagglutinin and Attenuate H1N1 Influenza Virus},
journal = {Viruses},
year = {2025},
doi = {10.3390/v18010032}
}
EUVIMED